RSS-Feed abonnieren
DOI: 10.1055/s-2008-1076725
© Georg Thieme Verlag KG Stuttgart · New York
Anxiety, Phobia and Nadolol Abuse: A Case Report
Publikationsverlauf
received 09.07.2007
revised 16.01.2008
accepted 28.01.2008
Publikationsdatum:
23. Juli 2008 (online)

In France, one of the main missions of CEIP (Centres for the assessment and Information on Pharmacodependence) is to collect data and assess the potential of dependence on psychoactive drugs (under French regulations it is mandatory for health professionals to notify the relevant territorial CEIP in case of drug abuse or pharmacodependence): we present the case of a 24-year-old man who developed dependence on nadolol. Dependence adverse effects are not listed actually in the beta-blocker drugs monograph. Clearly, it seems that their use can lead to abuse. Therefore it is essential to communicate with health professionals about this phenomena; particularly the increase of posologies must be supervised with great care. Thus, it is useful and important to draw the attention of doctors to the possible abuse and misuse of beta-blocker, which has not been published and is not listed actually in the drug monograph.
References
- 1 Aarons R, Nies A, Gal J, Hegstrand L, Molinoff P. Elevation of β-adrenergic receptor density in human lymphocytes after propranolol administration. J Clin Invest. 1980; 65 949-957
- 2 Barcellos Fontanella BJ. Social anxiety and propranolol abuse: a case study. Rev Bras Psiquiatr. 2003; 25 228-230
- 3 Bawert A, Fischer G. Addiction – who is not affected?. Wien Med Wochenschr. 2005; 155 549-561
-
4 DSM-IV .
Manuel diagnostique et statistique des troubles mentaux . 4èmeédition. Trad. Paris, Masson 1996 - 5 Jolliet-Riant P, Tillement JP. Drug transfer across the blood-brain barrier and improvement of brain delivery. Fundam Clin Pharmacol. 1999; 13 16-26
- 6 Stemmelin J, Cohen C, Terranova JP. et al . Stimulation of the beta(3)-adrenoreceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology. 2008; 33(3) 574-587
- 7 Victorri-Vigneau C, Guerlais M, Jolliet P. Abuse, dependence and withdrawal with gabapentin : first case report. Pharmacopsychiatry. 2007; 40 43-44
-
8 http://www.dopage.com consulted on June 30, 2006
Correspondence
C. Victorri-Vigneau
Centre d'Evaluation et d'Information sur la Pharmacodependance
Service de Pharmacologie Clinique
9 quai Moncousu
44093 Nantes cedex 1
France
Telefon: +33/2/4008 40 96
eMail: Caroline.vigneau@chu-nantes.fr